Tacrolimus/Methotrexate versus Cyclosporine/Methotrexate as Graft-versus-Host Disease Prophylaxis in Patients with Severe Aplastic Anemia Who Received Bone Marrow Transplantation from Unrelated Donors: Results of Matched Pair Analysis

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 12, 2009, Pages 1603-1608

  Yagasaki, Hiroshi ^a   Kojima, Seiji ^a   Yabe, Hiromasa ^b   Kato, Koji ^c   Kigasawa, Hisato ^d   Sakamaki, Hisashi ^e   Tsuchida, Masahiro ^f   Kato, Shunichi ^b   Kawase, Takakaza ^g   Muramatsu, Hideki ^a   Morishima, Yasuo ^g   Kodera, Yoshihisa ^h  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^d KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^e TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^f Ibaraki Children's Hospital   (Japan)

^g AICHI CANCER CENTER HOSPITAL   (Japan)

^h AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Aplastic anemia; Cyclosporine; Graft versus host disease; Prophylaxis; Tacrolimus; Unrelated bone marrow transplantation

Indexed keywords

CYCLOSPORIN; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; SURVIVAL RATE; UNRELATED DONOR;

ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MATCHED-PAIR ANALYSIS; METHOTREXATE; SURVIVAL RATE; TACROLIMUS; TISSUE DONORS;

EID: 70350569966     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.08.012     Document Type: Article

References (22)

1. Kojima S., Horibe K., Inaba J., et al. Long-term outcome of acquired aplastic anaemia in children: comparison between immunosuppressive therapy and bone marrow transplantation. Br J Haematol 111 (2000) 321-328
2. Davies J.K., and Guinan E.C. An update on the management of severe idiopathic aplastic anaemia in children. Br J Haematol 136 (2007) 549-564
3. Kojima S., Hibi S., Kosaka Y., et al. Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood 96 (2000) 2049-2054
4. Führer M., Rampf U., Baumann I., et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 106 (2005) 2102-2104
5. Kosaka Y., Yagasaki H., Sano K., et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 111 (2008) 1054-1059
6. Storb R., Deeg H.J., Farewell V., et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68 (1986) 119-125
7. Locatelli F., Bruno B., Zecca M., et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 96 (2000) 1690-1697
8. Liu J., Farmer Jr. J.D., Lane W.S., Friedman J., Weissman I., and Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66 (1991) 807-815
9. Bram R.J., Hung D.T., Martin P.K., Schreiber S.L., and Crabtree G.R. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol 13 (1993) 4760-4769
10. Hiraoka A., Ohashi Y., Okamoto S., et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 28 (2001) 181-185
11. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
12. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
13. Kojima S., Matsuyama T., Kato S., et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood 100 (2002) 799-803
14. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
15. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15 (1995) 825-828
16. Viollier R., Socié G., Tichelli A., et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 41 (2008) 45-50
17. Maury S., Balère-Appert M.L., Chir Z., et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 92 (2007) 589-596
18. Deeg H.J., O'Donnell M., Tolar J., et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 108 (2006) 1485-1491
19. Bacigalupo A., Locatelli F., Lanino E., et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant 36 (2005) 947-950
20. Margolis D., Camitta B., Pietryga D., et al. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. Br J Haematol 94 (1996) 65-72
21. Vassiliou G.S., Webb D.K., Pamphilon D., Knapper S., and Veys P.A. Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath. Br J Haematol 114 (2001) 701-705
22. Yanada M., Emi N., Naoe T., et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplant 34 (2004) 331-337